Experience with registered mucosal vaccines

被引：79

作者：

Dietrich, G ^{[1
]}

Griot-Wenk, M ^{[1
]}

Metcalfe, IC ^{[1
]}

Lang, AB ^{[1
]}

Viret, JF ^{[1
]}

机构：

[1] Berna Biotech Ltd, CH-3018 Bern, Switzerland

来源：

VACCINE | 2003年 / 21卷 / 7-8期

关键词：

mucosal vaccines; attenuated live vaccines; Salmonella typhi Ty21a; Vibrio cholerae CVD 103-HgR;

D O I：

10.1016/S0264-410X(02)00579-0

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 [免疫学];

摘要：

Most pathogens gain access to their host through mucosal surfaces. It is therefore desirable to develop vaccination strategies that lead to mucosal immune responses. Ideally, a vaccine should be administered mucosally in order to elicit mucosal protection. Several attenuated live viral and bacterial pathogens are registered as oral vaccines for human use, including the oral polio vaccine (Sabin) as well as attenuated strains of Salmonella typhi and Vibrio cholerae. These attenuated bacterial live vaccines-S. typhi Ty21a as well as V cholerae CVD 103-HgR-are employed as vaccines against typhoid and cholera, respectively. In this manuscript, we review the immune responses that are induced by these vaccines, with a focus on mucosal immunity. (C) 2002 Elsevier Science Ltd. All rights reserved.

引用

收藏

页码：678 / 683

页数：6

相关论文

共 32 条

[1]

Early phase II trial of human rotavirus vaccine candidate RV3 [J].

Barnes, GL ;

Lund, JS ;

Mitchell, SV ;

De Bruyn, L ;

Piggford, L ;

Smith, AL ;

Furmedge, J ;

Masendycz, PJ ;

Bugg, HC ;

Bogdanovic-Sakran, N ;

Carlin, JB ;

Bishop, RF .

VACCINE, 2002, 20 (23-24) :2950-2956

[2]

Brandtzaeg P., 1994, HDB MUCOSAL IMMUNOLO, P251

[3]

Vaccines and mucosal immunisation [J].

Cripps, AW ;

Kyd, JM ;

Foxwell, AR .

VACCINE, 2001, 19 (17-19) :2513-2515

[4]

SAFETY AND IMMUNOGENICITY OF A BOOSTER DOSE OF VIBRIO-CHOLERAE CVD-103-HGR LIVE ORAL CHOLERA VACCINE IN SWISS ADULTS [J].

CRYZ, SJ ;

LEVINE, MM ;

LOSONSKY, G ;

KAPER, JB ;

ALTHAUS, B .

INFECTION AND IMMUNITY, 1992, 60 (09) :3916-3917

[5]

IGA ANTIBODY-PRODUCING CELLS IN PERIPHERAL-BLOOD AFTER ANTIGEN INGESTION - EVIDENCE FOR A COMMON MUCOSAL IMMUNE-SYSTEM IN HUMANS [J].

CZERKINSKY, C ;

PRINCE, SJ ;

MICHALEK, SM ;

JACKSON, S ;

RUSSELL, MW ;

MOLDOVEANU, Z ;

MCGHEE, JR ;

MESTECKY, J .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (08) :2449-2453

[6]

ISOLATION AND CHARACTERIZATION OF GAL-E MUTANT TY 21A OF SALMONELLA-TYPHI - CANDIDATE STRAIN FOR A LIVE, ORAL TYPHOID VACCINE [J].

GERMANIER, R ;

FURER, E .

JOURNAL OF INFECTIOUS DISEASES, 1975, 131 (05) :553-558

[7]

ACTIVE IMMUNITY IS SEEN AS A REDUCTION IN THE CELL RESPONSE TO ORAL LIVE VACCINE [J].

KANTELE, A ;

KANTELE, JM ;

ARVILOMMI, H ;

MAKELA, PH .

VACCINE, 1991, 9 (06) :428-431

[8]

Kaul D, 1998, Dev Biol Stand, V95, P141

[9]

Local and systemic immune responses to combined Vibrio cholerae CVD103-HgR and Salmonella typhi Ty21a live oral vaccines after primary immunization and reimmunization [J].

Kollaritsch, H ;

Cryz, SJ ;

Lang, AB ;

Herzog, C ;

Que, JU ;

Wiedermann, G .

VACCINE, 2000, 18 (26) :3031-3039

[10]

LIVE ORAL VACCINES AGAINST CHOLERA - AN UPDATE [J].

LEVINE, MM ;

KAPER, JB .

VACCINE, 1993, 11 (02) :207-212

← 1 2 3 4 →